Circulating Endothelial Progenitor Cells and Aortic Aneurysm (ANOPEC3)

This study is not yet open for participant recruitment.
Verified August 2013 by Hopital Jean Minjoz
Sponsor:
Information provided by (Responsible Party):
Prof. Sidney Chocron, Hopital Jean Minjoz
ClinicalTrials.gov Identifier:
NCT01918982
First received: August 6, 2013
Last updated: August 7, 2013
Last verified: August 2013
  Purpose

We aimed to see if aortic aneurysms could be followed-up by circulating endothelial progenitor cells CD34+144+CD14- and CD34+VEGF-R2+CD14- blood level.


Condition
- Aortic Aneurysm

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Interest of Circulating Endothelial Progenitor Cells CD34+144+CD14- and CD34+VEGF-R2+CD14- in the Follow-up of Aortic Aneurysm

Resource links provided by NLM:


Further study details as provided by Hopital Jean Minjoz:

Primary Outcome Measures:
  • Circulating endothelial progenitor cells CD34+144+CD14- and CD34+VEGF-R2+CD14- blood concentration [ Time Frame: 2 years ] [ Designated as safety issue: No ]
    Patients are followed for 2 years


Estimated Enrollment: 40
Study Start Date: October 2013
Estimated Study Completion Date: May 2016
Estimated Primary Completion Date: February 2016 (Final data collection date for primary outcome measure)
Groups/Cohorts
Aortic aneurysm
Patients with aortic aneurysm >30mm and < 50mm

Detailed Description:

Circulating endothelial progenitor cells CD34+144+CD14- and CD34+VEGF-R2+CD14- have been shown to be inversely correlated to aortic aneurysm size. We aimed to see if aortic aneurysms could be followed-up by circulating endothelial progenitor cells CD34+144+CD14- and CD34+VEGF-R2+CD14- blood level. 40 patients followed for known aortic aneurysm >30mm and <50mm will be followed up every 6 months during 2 years. Each 6 months they will have a consultation by their physiologist with an echo or a CT-scan. At the same time, a 10ML blood sample will be taken to assess the circulating endothelial progenitor cells CD34+144+CD14- and CD34+VEGF-R2+CD14- blood level.

  Eligibility

Ages Eligible for Study:   18 Years to 85 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Patients with aortic aneurysm

Criteria

Inclusion Criteria:

  • Aortic aneurysm size >30mm and > 50mm

Exclusion Criteria:

  • Infectious disease
  • Inflammatory disease
  • Liver insuffisency
  • Cancer evolutive
  • Pregnant women
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01918982

Contacts
Contact: Sidney Chocron +33381533121 sidney.chocron@univ-fcomte.fr

Sponsors and Collaborators
Hopital Jean Minjoz
Investigators
Principal Investigator: Sidney Chocron, MD, PhD Université de Franche-comté. France
Principal Investigator: Andrea Perrotti, MD Université de Franche-Comté. France
Principal Investigator: Simon Rinckenbach, MD, PhD Université de Franche-Comté. France
Principal Investigator: Siamak Davani, MD, PhD Université de Franche-Comté. France
  More Information

Publications:
Responsible Party: Prof. Sidney Chocron, MD, PhD, Hopital Jean Minjoz
ClinicalTrials.gov Identifier: NCT01918982     History of Changes
Other Study ID Numbers: 147/362
Study First Received: August 6, 2013
Last Updated: August 7, 2013
Health Authority: France: Health Agency

Keywords provided by Hopital Jean Minjoz:
Aortic aneurysm
circulating endothelial progenitor cells

Additional relevant MeSH terms:
Aneurysm
Aortic Aneurysm
Vascular Diseases
Cardiovascular Diseases
Aortic Diseases

ClinicalTrials.gov processed this record on April 15, 2014